Merit Medical Systems Inc (MMSI) KPIs and segments
Close on Nov 17, 2026Market cap $5.06BP/E 31.8Yield –
KPIs & segments
Operating metrics and segments that drive Merit Medical Systems's business
Merit Medical Systems's revenue by segment, product and region, plus the counts and sizes it tags in its 10-K and 10-Q filings (XBRL). Each figure links to the filing it came from. A fuller KPI sheet built from earnings releases and presentations is on the way. See the segment tables for a trailing-twelve-month view, or how companies compare on operating metrics.
The chart is empty. Tick the box next to any metric in the table below to plot it — tick several to compare them on one chart.
| Add to chart | Metric | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Single reportable segment($M) | 416 | 419 | 382 | 384 | 382 | 355 | |||||||
Cardiovascular($M)4 | 374 | 366 | 364 | 339 | 338 | 323 | 328 | 313 | 315 | ||||
Peripheral Intervention($M) | 155 | 145 | 143 | 137 | 135 | 133 | 134 | 130 | 115 | ||||
Cardiac Intervention($M) | 117 | 117 | 115 | 99.7 | 95.2 | 90.2 | 93.3 | 90.2 | 88.4 | ||||
Custom Procedural Solutions($M) | 53.6 | 54.1 | 53.6 | 47.9 | 50.9 | 50.5 | 50.1 | 48.5 | 48.0 | ||||
OEM($M) | 48.1 | 50.8 | 52.3 | 53.8 | 56.3 | 49.1 | 50.0 | 44.6 | 63.6 | ||||
Endoscopy($M)1 | 20.1 | 17.7 | 18.4 | 16.6 | 17.5 | 17.0 | 10.2 | 10.1 | 9.29 | ||||
Endoscopy Devices($M) | 20.1 | 17.7 | 18.4 | 16.6 | 17.5 | 17.0 | 10.2 | 10.1 | 9.29 | ||||
Foundational($M) | 276 | 281 | 255 | 261 | 262 | 240 | |||||||
Access($M) | 158 | 162 | 152 | 152 | |||||||||
Therapeutic($M) | 141 | 138 | 126 | 123 | 120 | 115 | |||||||
Vascular Intervention($M) | 42.4 | 41.7 | 35.4 | 35.0 | |||||||||
Cardiac Therapies($M) | 27.5 | 28.5 | 25.5 | 22.9 | |||||||||
Procedural Solutions($M) | 27.2 | 27.9 | 32.3 | 31.7 | |||||||||
Oncology($M) | 27.1 | 25.8 | 23.3 | 23.9 | |||||||||
Endoscopy($M) | 23.4 | 23.6 | 17.6 | 18.4 | |||||||||
Renal Therapies($M) | 13.6 | 12.7 | 13.8 | 12.8 | |||||||||
OEM($M) | 13.1 | 12.8 | 9.95 | 9.74 | |||||||||
Other($M) | 2.01 | 1.24 | 0.22 | 0.35 | |||||||||
United States($M) | 256 | 252 | 227 | 238 | 231 | 227 | 214 | 214 | 206 | 195 | 186 | 189 | |
International($M) | 160 | 167 | 155 | 156 | 154 | 155 | 142 | 142 | 133 | 143 | 137 | 136 | |
Cardiovascular($M) | 48.6 | 37.8 | 41.2 | 38.5 | 36.8 | 37.6 | 42.9 | 32.9 | 31.5 | ||||
Endoscopy($M) | 5.62 | 4.83 | 5.64 | 2.50 | -0.21 | -0.29 | 3.03 | 3.02 | 2.14 | ||||
Single reportable segment($M) | 256 | 260 | 235 | 236 | 230 | 213 | |||||||
Cardiovascular($M) | 227 | 222 | 216 | 200 | 199 | 185 | 187 | 180 | |||||
Endoscopy($M) | 15.0 | 13.5 | 14.1 | 12.3 | 12.7 | 12.4 | 6.93 | 7.03 | |||||
Earlier reporting (last reported 2023)2 | |||||||||||||
8 metrics have no data in the last 12 quarters — .
Italic numbers are calculated by StockData from reported figures (hover for the formula). Numbers with a dotted underline are read from the text of earnings releases and presentations; hover to see the exact sentence. Tick a row to add it to the chart above (up to 8 lines).
Methodology and excluded metrics
- Core rows come from the segment and revenue-disaggregation notes of 10-K and 10-Q filings (XBRL), linked to each filing. Fourth-quarter figures are the fiscal year less the first nine months (shown in italic).
Data updated 2026-10-29.
See a number that looks wrong?